Protein Expression Global Market Report 2024

The protein expression market size has grown rapidly in recent years. It will grow from $3.19 billion in 2023 to $3.56 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth observed during the historical period can be attributed to several factors, including advancements in scientific research, the development of biopharmaceuticals, progress in biotechnology, activities related to drug discovery and development, and the expansion of the healthcare industry.

The protein expression market size is expected to see rapid growth in the next few years. It will grow to $5.7 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The projected growth in the forecast period can be attributed to various factors, including the adoption of personalized medicine, the expansion of the biosimilars market, drug repurposing efforts, regulatory support, and advancements in precision agriculture. Prominent trends in this forecast period include the use of cell-free expression systems, the utilization of CRISPR-Cas9 for gene editing, the development of sustainable bioprocessing techniques, the growth of contract research and manufacturing services, and the integration of multi-modal expression platforms.

The protein expression market is experiencing significant growth driven by the increasing demand for biologics in addressing various genetic disorders and chronic diseases. Biologics encompass medicines derived from living organisms or containing components of living organisms, such as proteins, tissues, genes, and vaccines. The growing utilization of biologics, including therapeutic proteins, for the treatment of chronic conditions like cancer, cardiovascular diseases, and genetic disorders, is fostering the need for protein expression devices and equipment. For example, as of September 2022, the World Health Organization reported that approximately 74% of global annual deaths, which amounted to 41 million, were due to non-communicable diseases (NCDs) or chronic diseases. Consequently, the surging demand for biologics is propelling the protein expression market. Additionally, the biologics market held a substantial share, exceeding a quarter of the entire pharmaceutical market in 2020, as reported by analysts. The global biologics market is anticipated to grow by 14.7% during 2021-2023.

The primary product categories related to protein expression consist of reagents, competent cells, expression vectors, services, and instruments. Reagents are substances or compounds introduced into a system to trigger a chemical reaction or to ascertain whether a reaction has occurred. Protein expression takes various forms, including yeast expression, mammalian expression, algae expression, insect expression, bacterial expression, and cell-free expression, all of which find applications in therapeutic, industrial, and research settings. Diverse end users of these protein expression products and services include pharmaceutical and biotechnology companies, academic research institutions, and contract research organizations.

The protein expression market research report is one of a series of new reports that provides protein expression market statistics, including protein expression industry global market size, regional shares, competitors with a protein expression market share, detailed protein expression market segments, market trends and opportunities, and any further data you may need to thrive in the protein expression industry. This protein expression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The protein expression market is expected to witness substantial growth, thanks to increased government funding in the biopharmaceutical industry. This funding supports companies and institutions engaged in developing new drugs and therapies by facilitating the creation of innovative protein expression technologies and reducing production costs. In September 2023, the National Center for Science and Engineering Statistics disclosed that federal agency commitments for research and experimental development (R&D) reached an all-time high of $190.2 billion in fiscal year 2021. This figure marked a 13.6% increase of $22.7 billion compared to fiscal year 2020's funding of $167.4 billion. Consequently, escalating government support for research in the biopharmaceutical sector is a driving force behind the protein expression market.

The protein expression market's growth may encounter hindrances due to government regulations concerning protein therapeutics and biologics production. These regulations impose rigorous preclinical and clinical trial requirements for biologics, leading to lengthy approval processes, with a primary focus on ensuring the health and safety of individuals. Marketing and distribution of biologics, which includes insulin, hormones, therapeutic antibodies, and vaccines, is contingent on successful completion of these clinical trials, which are often protracted, costly, and uncertain. For instance, the FDA stipulates that the approval of new biologics typically entails 10 to 12 months, with firms required to provide annual reports on the status of clinical safety, clinical efficacy, clinical pharmacology, and nonclinical toxicology studies.

Major players operating in the protein expression market are placing a greater emphasis on introducing next-generation solutions, such as the Visium CytAssist Gene and Protein Expression Assay, to optimize their market revenues. These next-generation solutions leverage advanced technologies and techniques to enhance the speed, accuracy, and efficiency of protein expression. In May 2023, 10x Genomics Inc., a US-based biotechnology company, launched the Visium CytAssist Gene and Protein Expression Assay, designed to enable researchers to explore protein expression patterns within the human immune system. The Visium approach distinguishes itself by performing H&E (Hematoxylin and Eosin) staining before applying any chemical treatments to tissue sections, facilitating three-dimensional spatial analysis on the same sample while preserving tissue morphology. This approach permits the collection of protein and whole transcriptome gene expression, along with histological analysis in a single experiment from a single tissue section.

The companies within the industry are increasingly incorporating Microfluidics technology into protein expression tests to reduce time, labor, and costs while improving accuracy and performance. Microfluidics technology offers enhanced analytical capabilities compared to traditional macroscale instruments. It is employed for assessing protein expression on cells and optimizing results related to protein expression. Therapeutics-on-a-chip (TOC) leverages microfluidic platforms to synthesize proteins in point-of-care settings, reducing the expenses associated with storing and transporting therapeutic proteins. Several companies, including MissionBio, NanoCellect Biomedical, RainDance Technologies, and Sphere fluidics, have implemented this technology in protein expression tests.

The protein expression market in the United States is governed by the Food and Drug Administration (FDA), which sets forth a series of guidelines for manufacturers and retailers within this industry. These FDA regulations ensure the quality, safety, and efficacy of biological therapeutics products while expediting innovations to make these products safer and more effective. The FDA has introduced initiatives to streamline the review of drugs and biologics to expedite the availability of therapies for patients with serious conditions and rare diseases, all while maintaining stringent safety and efficacy standards. Additionally, the European Medicines Agency has implemented policies aimed at encouraging academic groups and small companies to propose candidates for biologics by waiving scientific advice fees. These initiatives foster innovation in the field.

Major companies operating in the protein expression market include Agilent Technologies Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., New England Biolabs Inc., Promega Corporation, Qiagen NV, Takara Bio Inc., Merck KGaA, Genscript Biotech Corporation, Life Technologies Corporation, Sigma-Aldrich Corporation, Lucigen Corporation, Synthetic Genomics Inc., Becton, Dickinson & Company, Lonza Group Ltd., Geneva Biotech LLC, Viva Biotech Holdings, Sengenics LLC, ARTES Biotechnology GmbH, Addgene Inc., Profacgen, ProteoGenix Inc., Peak Proteins Ltd., Domainex Ltd., Jena Bioscience GmbH, EMD Millipore Corporation, Oxford Expression Technologies Ltd., Creative Biolabs Inc., Abnova Taiwan Corp, Accelagen Inc.

North America was the largest region in the protein expression market in 2023. Western Europe was the second largest region in the protein expression market. The regions covered in the protein expression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the protein expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The protein expression market includes revenue earned by instruments, expression kits, and systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.